KFAS
MIRM icon

Keating Financial Advisory Services’s Mirum Pharmaceuticals MIRM Stock Holding History

Keating Financial Advisory Services’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$462 Buy
5
+3
+150% +$282 ﹤0.01% 2274
2025
Q4 		$158 Buy
+2
New +$144 ﹤0.01% 2095

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Keating Financial Advisory Services's MIRM Position: Q1 2026 in Review

Keating Financial Advisory Services increased its Mirum Pharmaceuticals (MIRM) stake by 150% in Q1 2026, buying an estimated $282 and bringing the position to 5 shares worth $462. The position accounts for ﹤0.01% of the portfolio, ranked #2274.

Keating Financial Advisory Services first reported a position in MIRM in Q4 2025 and has held it in 2 quarters since. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Keating Financial Advisory Services held 5 shares of Mirum Pharmaceuticals worth $462 as of Q1 2026.
  • Keating Financial Advisory Services bought 3 Mirum Pharmaceuticals shares in Q1 2026, an estimated $282.
  • Mirum Pharmaceuticals made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q1 2026, its #2274 holding.
  • Keating Financial Advisory Services first reported a position in Mirum Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Keating Financial Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.